Articles related to GENITOURINARY CANCER

The results of PROfound and PROpel underscore the importance of identifying the genomic characteristics of the patient and the cancer to guide the selection of the most appropriate treatment for a specific patient type.

Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.

Understanding the impact of lymphovascular invasion on overall survival in RCC patients is crucial for surgical decision-making and postoperative care.

Delve into key insights from ASCO 2023, which emphasized patient-centered care in genitourinary oncology, including the efficacy of virtual prostate cancer clinics and the critical need for initiating serious-illness conversations.

Second-generation androgen receptor pathway inhibitors (ARPIs) have proven to be essential in managing nonmetastatic castration-resistant prostate cancer (nmCRPC). These treatments provide hope in delaying metastasis and improving overall survival, significantly altering the disease’s prognosis.